


## Electronic Supplementary Information

### Three-dimensional Angiography Fused with CT/MRI for Multimodal Imaging of Nanoparticles Based on $\text{Ba}_4\text{Yb}_3\text{F}_{17}$ : $\text{Lu}^{3+}$ , $\text{Gd}^{3+}$

Sihan Ma<sup>a,b</sup>, Jiaxin Zhang<sup>b</sup>, Shibo Xia<sup>b</sup>, Wenyan Yin<sup>b</sup>, Yanxia Qin<sup>b</sup>, Runhong Lei<sup>b</sup>, Jianglong Kong<sup>b</sup>,  
Linqiang Mei<sup>b</sup>, Juan Li<sup>\*,b</sup>, Gengmei Xin<sup>\*,b</sup> and Gongping Li<sup>\*,a</sup>



**Figure S1.** SEM and DLS images of multi-functional contrast agents. SEM images of (A)

LNs (B) LNs@PEG (C) LNs@PEG@GLN, DLS images of (D)-(F) hydration particle size

distribution of contrast agents LNPs, LNPs@PEG and LNPs@PEG@GLN, respectively. (G)

EDS image of LNPs. Displaying the composition of nanoparticles.

**Table S1.** Concentration-dependent CT value *in vitro*

Concentration	0mg/ml	1.2mg/ml	2.5mg/ml	5.3mg/ml	7.9mg/ml
<b>LNPs@PEG@GLN</b>	<b>161.1</b>	<b>210.6</b>	<b>258.7</b>	<b>324.5</b>	<b>426.3</b>
<b>Ioversol</b>	<b>168.3</b>	<b>201.5</b>	<b>250.1</b>	<b>305.3</b>	<b>375.5</b>

**Table S2.** MRI T<sub>1</sub>-weighted value *in vitro*

Gd <sup>3+</sup> Concentration (μM)	0	0.0113	0.0226	0.0294	0.0362
<b>LNPs@PEG@GLN (1/T<sub>1</sub>)</b>	<b>0.000339</b>	<b>0.000617</b>	<b>0.000951</b>	<b>0.001062</b>	<b>0.001255</b>

**Table S3.** MRI T<sub>2</sub>-weighted value *in vitro*

Concentration (μM)	0	0.071	0.141	0.184	0.226
<b>LNPs@PEG@GLN (1/T<sub>2</sub>)</b>	<b>0.00142</b>	<b>0.08104</b>	<b>0.14492</b>	<b>0.17857</b>	<b>0.20408</b>

**Table S4.** Fluorescence uptake value *in vitro*

Concentration (mg/ml)	0.5	1	3	6	9
-----------------------	-----	---	---	---	---

---

**LNPs@PEG@GLN****0.98****2.03****2.50****3.48****9.36**

---




Figure S2. DLS images for LNPs@PEG@GLN which were placed in different solution (water, PBS and PBS+FBS) at different time. Indicated the stability of nanoparticles at different environment.

**Table S5.** CT value for different organic *in vivo*

---

Time (min)	0	2	5	15
LNPs(liver)	332.4	345.3	340.0	425.3

---

<b>LNPs(spleen)</b>	<b>262.9</b>	<b>255.3</b>	<b>337.6</b>	<b>528.2</b>
<b>LNPs(bladder)</b>	<b>1472.1</b>	<b>1564.1</b>	<b>1468.2</b>	<b>1505.3</b>
<b>Ioversol(kidney)</b>	<b>486.0</b>	<b>528.0</b>	<b>615.5</b>	<b>533.5</b>
<b>Ioversol(bladder)</b>	<b>332.4</b>	<b>1021.2</b>	<b>1686.5</b>	<b>4620.0</b>
<b>Ioversol(spleen)</b>	<b>356.7</b>	<b>335.2</b>	<b>369.1</b>	<b>387.2</b>

---




Figure S3. CT 2D flat images before and after injection of LNPs@PEG@GLN (top) and Ioversol (bottom).




Figure S4 **Bio-distribution of multi-functional LNPs@PEG@GLN.** (A) CT signal of LNPs@PEG@GLN and (B) Ioversol at different tissues at different time respectively. (C) Dose of LNPs@PEG@GLN at different time points. Indicated the distribution of nanoparticles at different tissues.




Figure S5. High resolution CT 2D flat images after injection of LNPs@PEG@GLN.




Figure S6 2D fluorescence images at different time points (0 min, 2 min, 5 min, and 15 min) after injection of LNPs@PEG@GLN through the tail vein.



113002. avi

Movie S: 3D fluorescence imaging animation